MAPK1 and neoplasm: Of the 17 enrolled patients, nine (53%) had clinical to pathological tumor decline, suggesting that Trametinib significantly reduced Ras/MEK/ERK pathway activation and clinical and metabolic tumor response in patients with OSCC [107].